This is a routine conference presentation with no material new information. No trading action warranted. Monitor upcoming quarterly filings for TONMYA sales data and pipeline updates.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study characterizing fibromyalgia patients. The press release is a routine scientific conference update with no new financial data, clinical results, or regulatory catalysts — it does not change the company's commercial or pipeline outlook.
Key Facts
- Poster presentation at ISPOR 2026 (May 17-20, 2026) on a retrospective claims study of fibromyalgia patients using U.S. data from April 2021-April 2024.
- TONMYA (cyclobenzaprine HCl sublingual tablets) was FDA-approved on August 15, 2025, and commercially launched on November 17, 2025.
- No new clinical data, financial results, guidance, or regulatory updates were disclosed.
Financial Impact
No financial impact — the press release contains no revenue, earnings, or deal figures.
Risk Factors
- TONMYA commercial launch may underperform expectations given competitive fibromyalgia market.
- No new clinical or regulatory catalysts announced — pipeline timelines remain uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294716 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.39 (−5.93%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.39 (−16.04%) |
Oct 2, 2026 25d ago | 8-K | $8.07 | awaiting T+20 | — | $5.39 (+33.21%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.39 (−49.10%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.39 (−59.04%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.39 (−49.48%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.39 (−48.02%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.39 (−53.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers